anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses donkey-hide gelatin candied date brown sugar. The donkey-hide gelatin candied date brown sugar comprises the following components of the weight percentage: 75% to 85% of brown sugar, 10% to 15% of date powder, 1 to 10% of donkey-hide gelatin, 0.1% to 0.25% of citric acid and also contains 0.05 to 0.1% of ethyl maltol. The present invention also discloses a method for producing the donkey-hide gelatin candied date brown sugar. The donkey-hide gelatin in the donkey-hide gelatin candied date brown sugar of the present invention can enhance the immunity of an organism. A date has a control effect on deficiency of a spleen and a stomach, deficiency of qi and blood, cough due to deficiency of the lung, weakness due to a tired body, etc. The nature and the flavour of the brown sugar are warm, and the brown sugar has effects of removing blood stasis, promoting fluid, dispelling cold, activating blood, warming the stomach and strengthening the spleen. The food product is used as a drug and food through scientific compatibility, so the immunity of the organism can be improved, consenescence is prevented, and the physique of people is enhanced. The donkey-hide gelatin candied date brown sugar can be used as the drug when a person is ill and can be used as a tonic when the person is not ill. The present invention has the advantages of complete nutrient components, convenient eating and safety. Dosage is easily mastered to satisfy the demand of people for nutrient components, and the nutrient components can not be wasted, either.
A retrospective chart review of all patients presenting to Beaumont Health System emergency departments between December 15, 2020 and April 30, 2021 who tested positive for COVID-19 will be performed. The primary aim is to compare the rate of Emergency Department (ED) presentations/hospitalizations among unvaccinated, partially vaccinated, and fully vaccinated patients presenting to an emergency center (EC). Secondarily, the rates of individual clinical outcomes of COVID-19 infection for hospitalized patients will be compared among unvaccinated, partially vaccinated, and fully vaccinated patients, including the proportion of COVID-positive patients who develop severe disease, require admission to the hospital, and rates of those requiring intensive care unit (ICU) admission, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), renal replacement therapy (RRT), supplemental oxygenation, or noninvasive ventilation, as well as the rate of in-hospital mortality and the hospital length of stay. Exploratory outcomes may include comparisons among fully-vaccinated individuals receiving each of the three types of vaccines, and investigation of demographic, epidemiological, clinical and laboratory predictors of hospitalization. For each individual, data collected will include vital signs (temperature, blood pressure, heart rate, respiratory rate, pulse oximetry), demographics (age, gender, existing medical conditions), home medications, chief complaint from emergency provider note, duration of symptoms in days at the time of presentation from emergency provider note, chest X-ray or chest computed tomography (CT) results, and laboratory values. For patients who were admitted, data collected will include initial hospital admission unit (regular medical or surgical floor, progressive floor, intensive care unit), change in unit type during admission, oxygen therapy (none, nasal cannula, supplemental high flow oxygen, ventilator), days on high flow oxygen, days on ventilator, specific inpatient medical therapies, laboratory values, imaging results, hospital length of stay, and disposition from hospital (home, rehabilitation unit, death).
FIELD: medicinal industry. SUBSTANCE: invention relates to the complex application of protective sucrose-gelatinous-milk medium both in the lyophilization process and in bacterial biomass accumulation. Method involves the application of sucrose-gelatinous medium as carbohydrate supplement in industrial strains culturing and preliminary application of fat-free milk as substrate for lactobacilli followed by its addition as component of protective medium to the bacterial suspension composition before drying. Invention proposes to add lactobacilli of species Lactobacillus acidophilus additionally for the enhancement of biological activity of preparation. Invention can be used for production of probiotics. EFFECT: optimization of method of preparation preparing, enhanced biological activity of preparation. 2 cl, 2 tbl, 3 ex
PROBLEM TO BE SOLVED: To obtain a sunburn preventive excellent in water material and sweat resistance, by including an ultraviolet absorber and a specific polymer compound. SOLUTION: This sunburn preventive contains an ultraviolet absorber in combination with an acetylated hyaluronic acid. Preferably acetylated hyaluronic acid has the number of substitutions of the acetyl group of 2-4 on the average in a repeating structural unit of the formula (R<1> to R<4> are each H an acetyl group subjected to ester bond and at least two or more of R<1> to R<4> are acetyl groups on the average in each repeating unit; R<5> is H or an alkali metal atom). p-Aminobenzoic acid, homomenthyl-N-acetyl anthranilate may be cited as the ultraviolet absorber and the amount of it formulated is 0.01-50 wt.%. The amount of the acetylated hyaluronic acid formulated is 0.0001-10 wt.%. A film- forming agent such as a silicone resin may be added to the system so as to improve water resistance and oil resistance.
In a 12-week, double-blind, active-controlled study, 242 JRA patients 2 years to 17 years of age were treated with celecoxib or naproxen; 77 JRA patients were treated with celecoxib 3 mg/kg BID, 82 patients were treated with celecoxib 6 mg/kg BID, and 83 patients were treated with naproxen 7.5 mg/kg BID. The most commonly occurring (>5%) adverse events in celecoxib treated patients were headache, fever (pyrexia), upper abdominal pain, cough, nasopharyngitis, abdominal pain, nausea, arthralgia, diarrhea and vomiting. The most commonly occurring (>5%) adverse experiences for naproxen-treated patients were headache, nausea, vomiting, fever, upper abdominal pain, diarrhea, cough, abdominal pain, and dizziness (Table 2). Compared with naproxen, celecoxib at doses of 3 and 6 mg/kg BID had no observable deleterious effect on growth and development during the course of the 12-week doubleblind study. There was no substantial difference in the number of clinical exacerbations of uveitis or systemic features of JRA among treatment groups.

In a 12-week, open-label extension of the double-blind study described above, 202 JRA patients were treated with celecoxib 6 mg/kg BID. The incidence of adverse events was similar to that observed during the double-blind study; no unexpected adverse events of clinical importance emerged.

Table 2: Adverse Events Occurring in >5% of JRA Patients in Any Treatment Group, by System Organ Class (% of patients with events)

*Abnormal laboratory tests, which include: Prolonged activated partial thromboplastin time, Bacteriuria NOS present, Blood creatine phosphokinase increased, Blood culture positive, Blood glucose increased, Blood pressure increased, Blood uric acid increased, Hematocrit  
decreased, Hematuria present, Hemoglobin decreased, Liver function tests NOS abnormal, Proteinuria present, Transaminase NOS increased, Urine analysis abnormal NOS
This is a phase II randomized, double-blind placebo-controlled, crossover trial. The primary outcome of this trial is achieving durable eradication HPV infection determined by HPV negative test results achieved while on active treatment with AHCC and maintained for 6 month post supplementation and 12 months post completion of AHCC treatment for Group 1. We will follow all patients for at least 12 months and up to 30 months depending on success of achieving a negative HPV testing results. After receiving AHCC 3 grams x 6 months if positive at the end of 12 months of study treatment, they are considered a treatment failure. If negative after completion of 6 months of AHCC supplementation + 6 months of placebo, they will continue on study for another six months (2 visits) to confirm they remain HPV negative and durable response. Group 2 will serve as untreated control for all time points (end of supplementation, then 6, 9, and 12 months post end of AHCC supplementation.
Some patients with heatstroke also experience intracerebral hemorrhage (ICH). However, clinical case reports of heatstroke-induced ICH are rare. The risk factors for cerebral hemorrhage after heatstroke remain unknown. The present study evaluated the clinical characteristics and risk factors of patients with heatstroke-related ICH. In this retrospective observational study, we collected data on all ICHs after heatstroke occurred between 2012 and 2022. The characteristics of patients with heatstroke-induced ICH were described. The risk factors for cerebral hemorrhage after heatstroke were examined using logistic regression analysis. In total, 177 patients were included in this study, and 11 patients with ICH secondary to heatstroke were identified. Variables with P values of <.05 in univariate models, comparing the cerebral hemorrhage and control groups, included heatstroke cause, temperature, heart rate, respiratory rate, vasopressor use, mechanical ventilation use, Acute Physiology and Chronic Health Evaluation II, total bilirubin, creatinine, platelet count, prothrombin time, procalcitonin, creatine kinase, disseminated intravascular coagulation (DIC) occurrence, and DIC score. Multivariate logistic regression showed that heatstroke patients with higher DIC scores (odds ratio, 18.402, 95% confidence interval, 1.384-244.763, P = .027) and higher creatine kinase levels (odds ratio, 1.021, 95% confidence interval, 1.002-1.041, P = .033) were at a higher risk of developing ICH. The death rate was higher in the cerebral hemorrhage group than in the control group (P = .042). Heatstroke-related cerebral hemorrhage may be associated with elevated creatinine levels and DIC severity (International Society on Thrombosis and Hemostasis score) after heatstroke, and heatstroke with cerebral hemorrhage may accelerate death.
A system for relating user inputs to antidote labels using artificial intelligence. The system includes at least a server designed and configured to receive at least a user input datum. The at least a server is designed and configured to create at least an unsupervised machine-learning model as a function of the at least a user input datum and output at least a first proving element. The at least a server is configured to select at least a first training set as a function of the at least a user input datum and the at least a first probing element. The system includes at least a label learner operating on the at least a server configured to create at least a supervised machine-learning model using the at least a first training set and relate at least a user input datum to at least an antidote. At least a label learner is configured to generate at least an antidote output using the at least a user input datum and the at least a supervised machine-learning model.
The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
PURPOSE: A composition containing Eriobotrya japonica leaf extract or fraction thereof is provided to suppress DGAT and to prevent or treat DGAT-associated diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating DGAT(diacylglycerol acyltransferase)-associated disease contains Eriobotrya japonica leaf extract or fraction thereof as an active ingredient. The DGAT-associated diseases are insulin resistance syndrome, congestive heart failure, cancer, dyslipidemia, insulin resistant or non-alcoholic fatty liver. The extract is isolated using water, organic solvent, or mixture solvent thereof. The organic solvent is C1-3 alcohol, methanol, or ethanol. The fraction is a water fraction or chloroform fraction. A food composition for treating DGAT-associated diseases contains the Eriobotrya japonica leaf extract or fraction thereof as an active ingredient.
A predictive modeling method implemented on a computer for predicting patient outcomes and conditions from medical database records of a population of patients, and an optimization process of iterative variation of parameters of the method to achieve a best precision fit. Individual patient documents are created by concatenation of unstructured text fields from the patient's medical record, and these are processed using Natural Language Processing. A patient document corpus is built, and terms in the corpus are weighted and mapped to standard vocabularies. A term-by-document matrix is built and its dimensionality is reduced by Latent Semantic Indexing. Patient and term queries are combined and scored, producing a ranked list. The parameters of the model are iteratively optimized for an input list of patients with corresponding health score values.
The invention discloses 359aa polypeptide as well as a carrier and applications of 359aa polypeptide. By utilizing the bioengineering technology, a segment of DNA sequence corresponding to 359 amino acid polypeptides is subjected to genetic recombination, and then the segment of DNA sequence after genetic recombination is connected to a pcDNA3.1 eukaryotic expression vector. The digestion and sequence analysis prove that after successful recombination, the eukaryotic expression recombinant polypeptide is transfected to myocardial cells, the western blot proves the protein expression of polypeptide, and thus the recombination of polypeptide is realized; the function of resisting myocardium apoptosis after IR of the polypeptide is studied, and the cellular experiment shows that the polypeptide has the important protection function of inhibiting the myocardium cell apoptosis after IR. The polypeptide analogue is efficiently expressed, a purification process is simple, and the further large-scale preparation is benefited. A theoretical foundation can be provided for searching for the effective intervention targets for the cellular damage after IR and developing the novel treatment medicines. The 359aa polypeptide and the carrier have very important development prospects when applied to the clinic treatment of IR for realizing the long-term outcome after revascularization of the cardiac blood vessels.
Consists of 40 age-matched participants described above who will undergo imaging twice on the MAGNUS 3.0T MRI scanner at two distinct time points. The 2 MRI imaging sessions will be at least 2 weeks apart. One of the 2 visits will include a clinical MRI scan using the same MRI acquisition protocols used for Group A. Because age-matched Controls are not expected to exhibit structural and functional changes during the study period, it was not deemed necessary for the interval between scan-visit time points to be identical for all participants in Group B.
Whilst chronic fatigue syndrome (CFS) has been widely researched amongst women, studies investigating how men experience a CFS diagnosis is limited. This study utilised an interpretative phenomenological approach to interview five men who have a medical diagnosis of CFS. Six themes emerged to demonstrate the participants' experiences prior to, during and after obtaining their CFS diagnosis. Findings revealed that participants were initially reluctant to accept their condition, confounded by their perception that symptoms compromised their sense of masculinity. They also felt that healthcare professionals had limited recognition of CFS leading them to seek social support and legitimisation from other sources. The struggle to come to terms with a different lifestyle and sense of masculinity prevailed. Such knowledge could be effectively utilised by researchers, practitioners and employers to facilitate an increased understanding of male accounts of the condition and more bespoke interventions where required.
Teachers in implementation schools will be given access to training and resources to implement PeerLearning.net as a core component of instruction. Investigators will not create specific requirements of teachers but will ask that they deliver lessons with PeerLearning.net at least four times per month. Investigators will monitor all teacher usage and thus will be able to promote greater usage by (1) publicly acknowledging teachers that are using it frequently and experiencing success, and (2) targeting teachers who use it infrequently with additional resources and support to encourage more frequent use.
Blood draw for SSCVD test at baseline and 6 months (±50 days). SomaSignal Cardiovascular Risk (SSCVD) results will not be provided to the provider or participant until the 6-month visit.
PURPOSE: A vaccine containing avian metapneumovirus SC1509 strain for preventing avian metapneumovirus infection is provided to ensure efficiency against severe virus. CONSTITUTION: An avian metapneumovirus SC1509 strain is deposited in the number of KCTC 11576BP. The virus has a nucleic acid sequence of sequence number 5 and G protein encoded by nucleic acid sequence of sequence number 6. A vaccine is alive vaccine containing the avian metapneumovirus SC1509 strain. The vaccine is inactivated vaccine, sub-unit vaccine, vector vaccine, chimera vaccine, or DNA vaccine. The vaccine further contains an adjuvant as an excipient.
Oral H1-antihistamines are first treatment recommended for allergic rhinitis (Bousquet et al, 2008) however they do not completely alleviate symptoms. This new study will therefore assess the effect of Lactobacillus paracasei LP-33 in the management of nasal and ocular symptoms, in addition to H1-antihistamines treatment. The main objective is to evaluate the effect of Lactobacillus paracasei LP-33 on quality of life. Additionally allergic rhinitis symptoms (nasal and eye symptoms) and immunological parameters will be evaluated, before and during the supplementation. Lactobacillus paracasei LP-33 is targeting the general population and improving quality of life of people sensitized to allergens. The study will be conducted in Europe on adult subjects with persistent allergic rhinitis.
PURPOSE: Corneal neovascularization (CNV) impairs corneal transparency and visual acuity. The study aims to deepen our understanding of the molecules involved in CNV induced by alkali burns, facilitate a better grasp of CNV mechanisms, and uncover potential therapeutic targets.
METHODS: Eighty-four mice were selected for establishing CNV models via alkali burns. On days 3, 7, and 14 after the burns, corneal observations and histological investigations were conducted. An integrated analysis of RNA sequencing (RNA-seq)-based transcriptomics and label-free quantitative proteomics was performed in both normal and burned corneas. Bioinformatics approaches, encompassing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, were applied to discern differentially expressed genes (DEGs) and crucial signaling pathways. Four potentially CNV-related genes were validated using quantitative real-time PCR (qRT-PCR) and Western blot.
RESULTS: Significant CNV was observed on the seventh day. Forty-one genes were differentially expressed in neovascularized corneas, with 15 upregulated and 26 downregulated at both mRNA and protein levels. Bioinformatics analysis revealed that these DEGs participated in diverse biological processes, encompassing retinol and retinoic acid metabolism, neutrophil chemotaxis, and actin filament assembly, along with significant enrichment pathways like cytochrome P450, tyrosine, and phenylalanine metabolism. The upregulation of lymphocyte cytosolic protein 1 (LCP1) and cysteine and glycine-rich protein 2 (CSRP2) genes and the downregulation of transglutaminase 2 (TGM2) and transforming growth factor-beta-induced (TGFBI) genes were confirmed.
CONCLUSIONS: We analyzed gene expression differences in mouse corneas 7 days after alkali burns, finding 41 genes with altered expression. The exact role of these genes in CNV is not fully understood, but exploring angiogenesis-related molecules offers potential for CNV treatment or prevention.
Risk Summary

Spinosad, the active ingredient in Spinosad Topical Suspension, is not absorbed systemically following topical application, and maternal use is not expected to result in fetal exposure to the drug. Spinosad Topical Suspension contains benzyl alcohol. Topical benzyl alcohol is unlikely to be absorbed through the skin in clinically relevant amounts; therefore, maternal use is not expected to result in fetal exposure to the drug [ see Clinical Pharmacology (12.3)]. 

In animal reproduction studies, no adverse embryofetal effects were seen at oral doses of spinosad up to 200 mg/kg/day in pregnant rats or 50 mg/kg/day in pregnant rabbits administered during the period of organogenesis ( see Data). The available data do not allow the calculation of relevant comparisons between the systemic exposure of spinosad in animal studies to the systemic exposure that would be expected in humans after topical use of Spinosad Topical Suspension. 

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk for birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

Systemic embryofetal development studies were conducted in rats and rabbits. Oral doses of 10, 50 and 200 mg/kg/day spinosad were administered during the period of organogenesis (gestational days 6 – 15) to pregnant female rats. No adverse embryofetal effects were noted at any dose. Maternal toxicity occurred at 200 mg/kg/day. Oral doses of 2.5, 10, and 50 mg/kg/day spinosad were administered during the period of organogenesis (gestational days 7 – 19) to pregnant female rabbits. No adverse embryofetal effects were noted at any dose. Maternal toxicity occurred at 50 mg/kg/day.

A two-generation dietary reproduction study was conducted in rats. Oral doses of 3, 10, and 100 mg/kg/day spinosad were administered to male and female rats from 10-12 weeks prior to mating and throughout mating, parturition, and lactation. No reproductive/developmental toxicity was noted at doses up to 10 mg/kg/day. In the presence of maternal toxicity, increased dystocia in parturition, decreased gestation survival, decreased litter size, decreased pup body weight, and decreased neonatal survival occurred at a dose of 100 mg/kg/day.
The self-help programme consists of 10 text-based sessions and one supportive E-Mail a week. The programme employs cognitive-behavioural interventions. The theoretical background is the Dual Process Model by Stroebe and Schutt (1999).